CareDx, Inc.

305 articles with CareDx, Inc.

• CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association

  3/23/2023

  CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association.

• The American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance

  3/7/2023

  CareDx, Inc. announced the issuance of a new position statement by the American Society of Transplant Surgeons supporting the use of CareDx’s AlloSure® Kidney for organ transplant surveillance, and AlloSure Heart and AlloMap® Heart.

• CareDx Update Regarding Raymond James & Associates’ Conference

  3/6/2023

  CareDx, Inc. announced that the Company has determined not to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference scheduled for later today in light of scheduling conflicts.

• CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference

  3/6/2023

  CareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference.

• CareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit

  3/1/2023

  CareDx, Inc. today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023.

• CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting

  2/22/2023

  CareDx, Inc. today announced that it is showcasing the clinical value of multimodality and artificial intelligence innovation at the annual American Society of Transplantation Cutting Edge of Transplantation (CEoT) meeting taking place February 23-25, in Scottsdale, Arizona.

• CareDx to Report Fourth Quarter and Full Year 2022 Financial Results

  2/21/2023

  CareDx, Inc. announced it will report financial results for the fourth quarter and full year 2022 after market close on Monday, February 27, 2023.

• CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings

  2/16/2023

  CareDx, Inc. announced that it will be presenting its latest solutions to support the cellular transplant and therapy ecosystem at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® taking place February 15-19 in Orlando, Florida.

• JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice

  1/26/2023

  CareDx, Inc. announced that the Journal of the American College of Cardiology : Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy to a less invasive acute rejection monitoring protocol in clinical practice.

• CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium

  1/11/2023

  CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium.

• Independent Prospective Study Defines Reference Range for CareDx’s AlloSure for Long-Term Lung Transplant Surveillance

  12/1/2022

  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a new study published in Transplantation Direct1 which establishes a reference baseline when using AlloSure® Lung in the long-term surveillance of lung transplant patients.

• CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician Community

  11/11/2022

  CareDx Leads Scientific Evidence with Over 100 Peer-Reviewed Publications Supporting the Clinical Use of AlloSure and AlloMap for Organ Transplant Patients.

• CareDx Demonstrates Power of AlloSure and Digital Health Transplant Solutions at American Society of Nephrology Kidney Week

  11/2/2022

  CareDx, Inc. today announced that it will be sharing the latest data on AlloSure® Kidney and its patient-centered digital health solutions at the American Society of Nephrology (ASN) Kidney Week 2022 meeting being held November 3 - 6 in Orlando, Florida.

• Independent Longitudinal Study Finds CareDx’s AlloSure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

  11/1/2022

  CareDx, Inc. today announced the results of a new study published in the Clinical Journal of the American Society of Nephrology (CJASN)1 showing that CareDx’s AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) solution identifies early signs of allograft rejection and BK virus infection in pediatric kidney transplant patients.

• CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting

  10/25/2022

  CareDx, Inc. today announced its leading presence as a Diamond Level sponsor at the 48th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in Las Vegas, Nevada from October 24 to October 28.

• CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care

  9/29/2022

  CareDx, Inc. today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 - October 3.

• Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions

  9/27/2022

  CareDx, Inc. today announced a new peer-reviewed publication showing that AlloMap®, the industry’s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 resulted in less pain and fewer adverse events compared to heart biopsy.

• CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society

  9/12/2022

  CareDx Demonstrates Global Leadership at 29th International Congress of The Transplantation Society.

• CareDx Unveils New Patient-Centered Medication Management Features on AlloCare Mobile Health App

  8/4/2022

  CareDx, Inc. today announced that its AlloCare® mobile health app features expanded medication adherence and patient-provider communication capabilities resulting from the successful integration of MedActionPlan®, an acquisition made last year.

• CareDx Reports Second Quarter 2022 Results

  8/4/2022

  CareDx, Inc. reported financial results for the second quarter ended June 30, 2022.